The success of immune checkpoint inhibitors in cancer therapy continues to grow, but a complete understanding of their underlying mechanisms is still lacking. (immunology2018.org)
iTeos is now developing EOS200271 which is a synthetic, small molecule inhibitor of indoleamine 2,3 - dioxygenase (IDO1), which has demonstrated the same anti-tumour activity in multiple preclinical tumour models in combination with immune checkpoint inhibitors as competitors, but also has demonstrated superior brain penetration. (iteostherapeutics.com)
Autoantibodies as biomarkers: Circulating autoantibodies are powerful resources to aid in the diagnosis and treatment of autoimmune disorders, infectious diseases and cancer - especially with promising advances in immune checkpoint inhibitor therapy. (cdi-lab.com)